Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes
Valeria Grancini, Andrea Gramegna, Laura Zazzeron, Gianfranco Alicandro, Laura L Porcaro, Federica Piedepalumbo, Chiara Lanfranchi, Valeria Daccò, Emanuela Orsi, Francesco Blasi
Topics & Concepts
IvacaftorCystic fibrosisCystic fibrosis-related diabetesMedicineCystic fibrosis transmembrane conductance regulatorInternal medicineDiabetes mellitusCombination therapyInsulinEndocrinologyType 2 diabetesGastroenterologyImpaired glucose toleranceCystic Fibrosis Research Advances